J. Zimmermann, S. Herrlinger, A. Pruy, T. Metzger and C. Wanner, “Inflammation Enhances Cardiovascular Risk and Mortality in Hemodialysis Patients,” Kidney Internation, Vol. 55, No. 2, 1999, pp. 648-658.

has been cited by the following article:

• TITLE: Serum Alkaline Phosphatase Levels and Mortality of Chronic Hemodialysis Patients

  AUTHORS: Tetsuri Yamashita, Junichi Shizuku, Takashi Ohba, Takashi Kabaya, Kosaku Nitta

  KEYWORDS: Alkaline Phosphatase, Hemodialysis, Mortality, Secondary Hyperparathyroidism

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.2 No.4, September 30, 2011

  ABSTRACT: Objective: Alkaline phosphatase (ALP) is considered a biomarker of high bone turnover in hemodialysis (HD) patients with secondary hyperparathyroidism. This study was conducted to determine whether high serum ALP levels are associated with increased all-cause mortality of HD patients. Patients and Methods: This was a retrospective cohort study conducted at a single center. The subjects were 195 patients on chronic HD therapy who were followed up for a 5 years, and relationships between their baseline data and outcomes were assessed statistically. The serum ALP level was used as the predictor, and the primary end point was all-cause mortality. Results: Based on the median serum ALP of 236 IU/L, the subjects were divided into a low-ALP group (Conclusion: High baseline serum ALP levels are associated with increased mortality of HD patients, independent of bone metabolism parameters and serum liver enzyme levels. ALP is a potential target for the treatment of HD patients.